PAM50 intrinsic subtype in hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial

被引：4
|
作者：
Prat, A. [1 ]
Brase, J. C. [2 ]
Cheng, Y. [3 ]
Nuciforo, P. [4 ]
Pare, L. [1 ]
Pascual, T. [1 ]
Martinez, D. [1 ]
Galvan, P. [1 ]
Vidal, M. [1 ]
Adamo, B. [1 ]
Hortobagyi, G. [5 ]
Baselga, J. [6 ]
Ciruelos, E. [7 ]
机构：
[1] Hosp Clin Barcelona, Dept Clin Oncol, Barcelona, Spain
[2] Novartis Pharma AG, Precis Med, Basel, Switzerland
[3] Novartis Pharma AG, Biostat, Basel, Switzerland
[4] Vall dHebron Inst Oncol, Mol Oncol, Barcelona, Spain
[5] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX 77030 USA
[6] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA
[7] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷
关键词：
D O I：
10.1016/S0959-8049(18)30574-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
404 (PB-03
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [1] Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2
    Prat, Aleix
    Christoph Brase, Jan
    Cheng, Yuan
    Nuciforo, Paolo
    Pare, Laia
    Pascual, Tomas
    Martinez, Debora
    Galvan, Patricia
    Vidal, Maria
    Adamo, Barbara
    Hortobagyi, Gabriel N.
    Baselga, Jose
    Ciruelos, Eva
    [J]. ONCOLOGIST, 2019, 24 (07): : 893 - 900
  • [2] Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2
    Piccart, M.
    Hortobagyi, G. N.
    Campone, M.
    Pritchard, K. I.
    Noguchi, S.
    Rugo, H.
    Gnant, M.
    Feng, W.
    Taran, T.
    Baselga, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : S1 - S1
  • [3] Everolimus (EVE) plus exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study
    Jerusalem, Guy Heinrich Maria
    Kovalenko, Elena
    Yardley, Denise A.
    De Boer, Richard H.
    Hurvitz, Sara A.
    Ejlertsen, Bent
    Blau, Sibel
    Ozguroglu, Mustafa
    Landherr, Laszlo
    Ewertz, Marianne
    Taran, Tanya
    Fan, Jenna
    Noel-Baron, Florence
    Louveau, Anne-Laure
    Burris, Howard A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2
    Hortobagyi, Gabriel N.
    Chen, David
    Piccart, Martine
    Rugo, Hope S.
    Burris, Howard A., III
    Pritchard, Kathleen I.
    Campone, Mario
    Noguchi, Shinzaburo
    Perez, Alejandra T.
    Deleu, Ines
    Shtivelband, Mikhail
    Masuda, Norikazu
    Dakhil, Shaker
    Anderson, Ian
    Robinson, Douglas M.
    He, Wei
    Garg, Abhishek
    McDonald, E. Robert, III
    Bitter, Hans
    Huang, Alan
    Taran, Tetiana
    Bachelot, Thomas
    Lebrun, Fabienne
    Lebwohl, David
    Baselga, Jose
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (05) : 419 - U79
  • [5] ECONOMIC ANALYSIS OF COMBINATION THERAPY WITH ALPELISIB AND FULVESTRANT FOR TREATMENT OF HORMONE RECEPTOR-POSITIVE (HR plus ) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER
    Delevry, D.
    Le, Q. A.
    [J]. VALUE IN HEALTH, 2020, 23 : S32 - S33
  • [6] BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)
    Royce, M.
    Villanueva, C.
    Ozguroglu, M.
    Bachelot, T.
    Azevedo, S.
    Melo Cruz, F.
    Hegg, R.
    Debled, M.
    Gradishar, W. J.
    Manlius, C.
    Ridolfi, A.
    Lin, J.
    Ringeisen, F.
    Cardoso, F.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [7] The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
    Beaver, Julia A.
    Park, Ben H.
    [J]. FUTURE ONCOLOGY, 2012, 8 (06) : 651 - 657
  • [8] Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
    Piccart, M.
    Hortobagyi, G. N.
    Campone, M.
    Pritchard, K. I.
    Lebrun, F.
    Ito, Y.
    Noguchi, S.
    Perez, A.
    Rugo, H. S.
    Deleu, I.
    Burris, H. A., III
    Provencher, L.
    Neven, P.
    Gnant, M.
    Shtivelband, M.
    Wu, C.
    Fan, J.
    Feng, W.
    Taran, T.
    Baselga, J.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (12) : 2357 - 2362
  • [9] Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2-advanced breast cancer
    Burris, H.
    Gnant, M.
    Hortobagyi, G.
    Hart, L.
    Yardley, D. A.
    Eakle, J.
    Provencher, L.
    Brechenmacher, T.
    Saletan, S.
    Taran, T.
    Rugo, H.
    [J]. CANCER RESEARCH, 2013, 73
  • [10] Ribociclib plus letrozole in premenopausal patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Razeq, Hikmat Abdel
    Cottu, Paul
    Ring, Alistair
    De laurentiis, Michelino
    Lu, Janice
    Azim, Hamdy
    Zamagni, Claudio
    Zhou, Katie
    Wu, Jiwen
    Menon-Singh, Lakshmi
    Martin, Miguel
    [J]. CANCER RESEARCH, 2021, 81 (04)
12345